Slingshot members are tracking this event:
Bayer (BAYRY) Announces Regulatory Submission of Regorafenib in Second-Line Treatment of Liver Cancer in U.S, Europe, and Japan
Slingshot Insights Explained
Nov 07, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Regulatory Submission, Regorafenib, Second-line Treatment, Liver Cancer, U.s, Japan, Europe, Fda, Ema, Phase 3, Resorce